ReviewBioengineering (Basel, Switzerland)2025
Advances in Targeted Delivery of Doxorubicin for Cancer Chemotherapy.
Review in Bioengineering (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Doxorubicin-induced hepatotoxicity: a multifaceted pathogenesis from mitochondrial collapse to immune remodeling and epigenetic memory.Archives of toxicology · 2026Review
- Recent Advances in Conjugation Chemistry Expanding the Applications of the DNA Tetrahedron.Chemical biology & drug design · 2026Review
- Framework Nucleic Acids as a Nanocontainer for Delivering Heterogeneous Molecular Drugs.Pharmaceutics · 2026Review
- Tailoring the Design of Dendritic Thermogels Through Carbosilane and Polyglycerol Crosslinkers.Pharmaceutics · 2026Article
- Curcumin Synergistically Sensitizes Multidrug-Resistant Lung Cancer to Doxorubicin Through Ferroptosis-Associated Oxidative Stress.Antioxidants (Basel, Switzerland) · 2026Article
- FeRSC advances · 2026Article
- Magnetic Nanocarriers with ICPTES- and GPTMS-Functionalized Quaternary Chitosan for pH-Responsive Doxorubicin Release.Biomolecules · 2026Article
- Zn-Ni metal-organic framework nanosheets@graphene oxide nanocomposite: A promising voltammetric platform for sensitive determination of doxorubicin.ADMET & DMPK · 2026Article
- Chitosan-coated mesoporous silica nanoparticles for pH-responsive doxorubicin delivery in head and neck cancer.Frontiers in bioengineering and biotechnology · 2026Article
- Positively charged liposomal β-carotene enhances irradiation-induced cytotoxicity against prostate carcinoma cells: an in-vitro study.BMC cancer · 2025Article
- Green synthesized mesoporous silica nanoparticles offer a promising drug delivery system investigated in physiologically relevant 3D microfluidic models.RSC advances · 2025Article
- Review
- Tumor-derived extracellular vesicles mediate cell-specific uptake and facilitate enhanced doxorubicin delivery in breast cancer.Frontiers in pharmacology · 2025Article
- Quercetin: A Natural Ally in Combating Breast Cancer.International journal of nanomedicine · 2025Review
- Novel Oncologic Strategies in Osteosarcoma Management: Maximizing Impact, Minimizing Harm.Discoveries (Craiova, Romania)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Doxorubicin (DOX) is one of the most powerful chemotherapy drugs used to treat different kinds of cancer. However, its usage has been limited by typical side effects and drug resistance, particularly cardiotoxicity. According to studies, a more effective and promising method is to conjugate it or entrap it in biocompatible nanoparticles. Compared to free DOX and traditional formulations, nanoparticles using specific processes or techniques can improve drug stability, minimize premature release at untargeted locations, and lower systemic toxicity. This review explains how various nanocarriers target the tumor to improve therapeutic efficacy while reducing the negative effects of DOX.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.